Date:1/18/2008

>The Src inhibitor AZD0530 developed by AstraZeneca is currently in early clinical trials. If the results seen in the laboratory can be reproduced in the clinic, this approach could offer a substantial clinical benefit to a large number of women with breast cancer, as Professor Robert Nicholson, Director of the Tenovus Centre for Cancer Research, explains:

Whilst little is known about the mechanisms used by breast cancers to become resistant to common therapies such as tamoxifen, it remains a significant clinical problem. Therefore the ability to restore sensitivity to therapy, or to even prevent resistance arising in the first place, could be of huge benefit to a large number of breast cancer patients.

'/>"/>

Contact: Lowri Jones joneslc3@cardiff.ac.uk 029-208-70995 Cardiff University Source:Eurekalert

2 GOOD

Page: 1 2
Related biology news :

1. Further development of Water Framework Directive necessary
2. Male contraception breakthroughs to be presented, Seattle Sept. 27-28
3. Breast cancer cells have to learn to walk before they can run
4. Varying prevalence among ethnic groups of gene mutation that increases risk of breast cancer
5. CSHL scientists identify and repress breast cancer stem cells in mouse tissue
6. New study reveals for first time how BRCA1 mutations cause breast cancer
7. Purdue research finds similarities in dog, human breast cancer pre-malignant lesions
8. Cell response to stress signals predicts tumors in women with common pre-breast cancer
9. Breastfeeding boost IQ in infants with helpful genetic variant
10. Breast cancer research and inkjet tissue printing get NSF boost
11. Einstein researchers receive grants totaling $700,000 for innovative breast cancer research